Member Info for shandypants2

soley - per head to Dish is 50p or £1 so lets go with your 80p average (can't be £1 as that's the maxmium not the average).

If the average is 2.6 people per booking that's c£2 per booking to DISH.

c150 restaurants at say 5 bookings each per day (i think this is a generous estimate) does give £1500 per day which whilst higher than my £1k estimate is still nowhere near the cost of rolling this out.

The 150 restaurants needs to be 10 or 100 times that and with only a few sales people the expansion is slow.

Don't get me wrong this is a great idea and has potential but just because it has worked in Asia doesn't mean it will translate to UK.

I will wait until some financial figures are published before dipping my toe in - i have learned from experience not to trust CEOs until there are numbers to back it up. Just my opinion, good luck to all.

Asked IDP investor relations a few questions on progress. No real surprises in the responses, other than confirmation that Roots is in 273 Asda stores.

Q and A below

ST and Roots – is this now in Asda – if so how many stores is this in
• Roots and Skinny Tan are online and in a small number of Asda stores. Roots is listed in 273 ASDA stores

Growlase.com – this appears now live now in US. Please confirm if this is now being actively sold - if so should there be a RNS to announce this. Is this sold outside of US?
• Growlase is only being sold in the US via DTC at the moment. As it is quite a small part of the business and not material, we are not able to announce it via RNS

Prolong – has marketing of this product recommenced. Is this still only sold in US and Australia
• Prolong is being sold via DTC in US and Australia and will be launched in the UK in the near future

Risky I see what your saying but firstly it was SOH who stated monthly revenue is now exceeding standard costs which indicates there is sufficient 'steady' revenue flow. Secondly, whilst payment will, as you state, be coming in as quarterly or half yearly lump sums we have 37 or so deals n place now so these will be spread over the year - so each month a number of these will drop.

Clearly some deals are larger than others so there will be a few bumps but it's far to state that an upward trend should be evident - unless of course revenues are not increasing as quickly as we would like!

SOH has already stated that monthly revenues are covering 'standard' monthly costs (i.e not R&D one off costs etc) so we are definitely over £100k per month but clearly it is the increase per month that will be of most interest

incidentally use code DELIVERFREE for free delivery via DTC.

If you have shares in this company you should have at least trialled the products.

I'm not a fake tanner myself but Roots is a great shampoo

https://www.skinnytan.co.uk/products/new-wonder-serum-launch-offer

Hopefully onwards and upwards now

Drax - breakeven in Q2??

They receive £1 or 50p per booking. this is light years away from breaking even.

Coverage is the key here and exploit 1st to market advantage.

Once this is in big cities and some chains have signed up then revenue will increase - for now I suspect it is a less than £1,000 per day

and 4 director purchases in last 2 months too. Bodes well IMHO

some decent size buying today (and no sells) yet price stubbornly refusing to budge.

Surely this can't be held back for too long.

Steady rise over the next 2 months IMHO

how can this product be found on the Boots site - I can't see it listed under any of the department searches?

The only way I can find it is to search directly for MyLotus and then it appears.

If we want to drive online footfall surely we need people to stumble across it and this seems problematic.

Clearly PR should be ramped up now after the great news re first pregnancies but that all costs money and as the results show CPT has a limited amount of that.

Has the company estimated sales for 2019 and 2020??

another Board share purchase.

This is now 3 separate ones in the space of a month or so and to me without a RNS is an indication that H2 is progressing well.

Obviously DYOR but if final numbers are decent this share should re-rate as the forward PE is c10 which is mega low for a growing share

https://prolongdevice.com/pages/better-sex

it's current being sold in Australia and USA only via DTC.

Sales were c£1k per day for H1 without advertising. Marketing was meant to have restarted in H2 so hopefully sells have increased.

No news on European roll out dates

Until there is a clear indication that year end targets will be hit , or at least comes close to hitting, this share appears to be flatlining.

There is progress though.

Boots ST seems to be going well, especially the new wonder serum which is regularly selling out at the Boots i've visited and also currently via IDPs DTC.

Growlase.com is now definitely live so this could have justified a RNS. Although sold in the US it is available for shipping to the UK (use code launch100 to get $100 off).

Roots seems to have stalled a little - still in the 200s (out of 470 in Boots bestselling shampoos) and Tesco sales look quiet too (based on number on shelf). Also noticed have lost top shelf position at SD.

It will be difficult for IDP to provide any additional revenue guidance as H2 was always dependent on the last few months and we are in the middle of this period. Therefore we may have to wait until mid June, as per previous years, to know where we stand.

The share price has always factored in minimal growth so a 20% revenue increase (from 10.7m to 12.8m) will still represent a decent performance despite missing the £14m guidance, especially as H1 was so disappointing. We also need to announce record profits so above £1.1m would be a decent figure, although i think guidance was c£1.5m.

The recent board purchases, especially the CEO one, may be an indicator that things are progressing to plan.

i don't think anyone is saying the CEO shouldn't earn more but his pay does appear overly generous and bonuses undemanding. Also since his health issues a few years ago he has cut down on his hours considerably , but his pay has increased.

The £37k median pay will be enhanced by the London sites - other massive sites such as Halifax (c2,000 employees) will earn considerably less.

I also note that his pension contribution was cut to 33% and this was compared to 13% for staff. What it doesn't say is that the staff final salary scheme has been frozen so the contribution paid by the company is fixed on your 2016 salary.

Is he doing a great job as CEO? The share price would say not. However, there are still cost savings to be made (there are duplication of roles across sites etc) and as most savings accounts pay 0.2% it appears margins can be maintained.
Furthermore after PPI hopefully there are no other massive legacy issues to resolve.

Incidentally I believe he has a massive amount of share options too (in addition to c15m shares). I'm told the exercise price is 90p. I suspect he will hang around for that

local Boots shelves were almost bare this time but nice to see re-stocked today in time for Bank Holiday weekend. Despite this wonder serum only had 2 bottles left so this is clearly selling extremely well.

It is up to 28th at Boots although only 1 other ST product (coconut mist) in top 100.

Seems to be the wonder serum is carrying ST a bit.

Just had a weekend in Dublin so nipped into a Boots there. ST has been in Ireland for c18 months. It is on the shelves but not many SKUs and no top shelf placement. Slightly uninspiring.

Noticed Boots have slightly expanded Roots range with the colour shampoo added so that's a positive.

good solid numbers and H2 going well too so healthy YE figures will give us a P/E under 10 and a valuation of significantly less than 1 x revenue. Both seem massively undervalued for a growth stock. Often the case when a growth stock stops growing the share gets hit overly hard and it takes time for trust to return.

I think the YE profit target of £8.7m seems conservative so i think this is a steal under £1 IMHO. Even with the decent share increase over last few weeks i can see another 50% increase over the next 18 months.

agree, only a small purchase but surely an indication outside of a RNS that sales are going well.

Onwards and upwards hopefully

https://www.drfertility.co.uk/collections/fertility-monitors/products/mylotus-fertility-monitor

found it here too, my issue is we need significant PR to raise awareness of the product and explain why it is better than the other fertility test kits available, all of which are a lot cheaper.

You go to Boot.com to buy beauty products not a £350 fertility test kit unless you have been directed elsewhere to do so

the wonder serum seems to be a great success - up to 44 in Boots best sellers list (out of 200). Only 1 other ST product (coconut mist) in top 100 and most products below 150.

Difficult to gauge in store sells but shelves I've seen in a few stores have limited supplies of the serum which would indicate it's selling well .

well Prolong did 100k in May and June last year so i would expect similar from Growlase between now and year end (30/6).

There are a couple of other products in this space too, unlike Prolong, which may limit sells.

It will be sold DTC and HC is always telling us how great IDP is at DTC so hopefully it will do ok. However, Prolong has thus far disappointed - still awaiting a European launch. I'm only expecting Prolong revenues of c£250k this year - initially i was hoping for double that.